2. Forward-looking Statements
Forward-looking Statements
Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements
regarding our expectations with respect to future growth and performance, the market potential for pipeline assets, the closing of the
Medicis acquisition and the timing of related regulatory approvals, integration planning and expected revenue and synergies associated
with the Medicis acquisition, the composition of the future Medicis management team, future cash returns with respect to acquisitions,
expectations with respect to partnering rights and journal publication with respect to efinaconazole, expectations with respect to gross
margins, certain expenses and the collection of receivables, future debt amounts and ratios, and financial guidance for 2012, including
expected revenues, adjusted cash flow from operations and cash EPS for 2012 and the fourth quarter of 2012. Forward-looking
statements may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,”
“may,” “will,” “believes,” “estimates,” “potential,” “targets,” or “continue” and variations or similar expressions. These statements are
based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are
not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and
Exchange Commission and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the
Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue
reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company
undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this
presentation or to reflect actual outcomes.
Non-GAAP Information
To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses
non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product
assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-
related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of
business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt
discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net,
(gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for
strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures,
management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends
for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not
necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the
corresponding measures calculated in accordance with GAAP.
Note 1: The guidance in this presentation is only effective as of the date given,
November 2, 2012, and will not be updated or affirmed unless and until the Company
publicly announces updated or affirmed guidance.
1
3. Agenda
1. Third Quarter Results and Performance
2. Performance of Deals and Recent Events
3. Medicis and IPD-108 (efinaconazole) Updates
4. Financial Update
5. 2012 Guidance Update
2
4. Q3 Revenue and Earnings Growth
No one-time items reported in Q3 2011 or Q3 2012
Q3 2012
Q3 2012 Q3 2011 vs
Q3 2011
Total Revenue $884 M $601 M 47%
Product Sales $857 M $570 M 50%
Cash EPS $1.15 $0.66 74%
3
5. 2012 Organic Growth
Same Store Sales*
Q3 2012 2012 YTD
U.S. Derm 62% 40%
U.S. Neuro -1% -6%
Canada / Australia -6% 4%
Emerging Markets 8% 11%
Total 14% 9%
Pro Forma*
Q3 2012 2012 YTD
U.S. Derm 35% 30%
U.S. Neuro -1% -6%
Canada / Australia -5% 4%
Emerging Markets 9% 13%
Total 12% 11%
* Adjusts for the impact of foreign exchange, acquisitions, divestitures/discontinuations, and includes JV revenues.
4
6. Price vs. Volume Growth
September 2012 YTD
Adjusts for the impact of acquisitions, divestitures/discontinuations,
and includes JV revenues
Price Volume
U.S. Derm 8% 22%
U.S. Neuro 5% -11%
Canada/Australia -2% 6%
Emerging Markets -1% 14%
Total Company 3% 8%
5
7. Revenue Performance of Past Acquisitions
LTM prior On Track or
to close 2012 Forecast Ahead of
Acquisition Date (USD $M's) (USD $M's) CAGR Deal Model
Coria Oct-08 $28.6 $85.4 28% Yes
Dow/Acanya Dec-08 $36.6 $90.3 23% Yes
Aton May-10 $68.0 $129.1 26% Yes
PharmaSwiss Mar-11 $221.3 $225.6 1% Yes
Zovirax (US & Canada) Feb-11 $169.6 $258.9 29% Yes
Elidel May-11 $43.1 $80.8 43% Yes
Sanitas Aug-11 $120.0 $144.4 12% Yes
Afexa Oct-11 $43.2 $30.3 -35% No
Ortho Dec-11 $150.5 $150.2 0% Yes
Dermik Dec-11 $242.1 $236.6 -2% Yes
Inova Dec-11 $186.6 $205.7 10% Yes
Total $1,309.7 $1,637.2 12%
LTM prior to close as been adjusted to reflect 2012 foreign exchange rates
Note: Excludes deals under $75 million purchase price and transactions completed in 2012 6
8. Performance of Past Acquisitions
Cash Flow vs. Deal Model
Behind by More Ahead by More Than
Acquisition Than 10% On Track 10%
Coria P
Dow/Acanya/111 P
Aton P
PharmaSwiss P
Zovirax (US & Canada) P
Elidel P
Sanitas P
Afexa P
Ortho P
Dermik P
Inova P
Total P
Note: Excludes deals under $75 million purchase price and transactions completed in 2012
7
9. Acquisitions – Cash Payback
(USD in millions)
Cash
Date Cash Generated Purchase Payback to
Acquisition Acquired Since Close Price Date
Coria Oct-08 $133 $95 1.40
Dow/Acanya Dec-08 $292 $400 0.73
Aton May-10 $192 $318 0.60
Biovail (incl. Zovirax) Sep-10 $1,538 $2,636 0.58
PharmaSwiss Mar-11 $98 $491 0.20
Elidel May-11 $97 $99 0.98
Sanitas Aug-11 $99 $448 0.22
Afexa Oct-11 $12 $92 0.13
Ortho Dec-11 $107 $346 0.31
Dermik Dec-11 $119 $421 0.28
Inova Dec-11 $86 $657 0.13
Note: Excludes deals under $75 million purchase price and transactions completed in 2012
8
10. Medicis Update
Medicis stockholder meeting scheduled for 12/7/12
HSR filed in September
Pulled and re-filed in October
Expect response by end of November
Integration planning ahead of schedule
Highly collaborative process
Expect planning to be complete by end of November
Cost synergies now expected to significantly exceed $225 million
New “Medicis” management team expected to
consist of both Medicis and Valeant executives
9
11. Significant Business Development
Activities
Sales
Company Acquired Assets Territories Revenue Purchase Multiple
Price Paid
Shower to Shower; U.S; Canada;
Ambi; Caladryl; South East
J&J* Purpose; Cortaid; Asia; Australia; N/A $153 million 2.2X
Corn Huskers; South Africa;
Cortef Latin America
Visudyne** U.S. Rights to U.S ~$21million $50.5 million 2.4X
Visudyne
Visudyne Non-U.S. Royalties ROW ~$14 million $50 million 3.6X
on Visudyne
* Not all products in every market
** Also purchased $12 million for multiple years of Visudyne inventory (primarily API)
10
12. Efinaconazole (IDP-108) Update
PDUFA date May 26, 2013
We now have worldwide rights
Except for Japan, China, Taiwan and South Korea
Plan to file in all territories where commercially viable
Looking for partners in territories we are not operating in
Filed with Health Canada in October
Kaken filed NDA in Japan in October
Expect publication in leading dermatology journal by year end
2012
11
16. Cash Flow
Q1 2012 Q2 2012 Q3 2012 YTD 2012
GAAP Cash Flow from $167.2 M $254.6 M $166.8 M $588.6 M
Operations
Adjusted Cash Flow $321.6 M $307.5 M $241.2 M $870.3 M
from Operations
Q3 GAAP Cash Flows impacted Full Year Adjusted Cash Flow from
by: Operations guidance reduced to
Restructuring and Integration $1.2 - $1.3 billion
costs of $34.2 million which Q4 Adjusted Cash Flow from
decreased vs Q2 and Q1 Operations $330-$430 million
Payment of accrued legal Lower Full Year Adjusted Cash Flow
settlement costs of $37.7 million from Operations driven by:
Increased working capital of Strong Emerging Markets Growth
$127.9 million, including an Working Capital investments in
increase in A/R of $182.6 M due acquired businesses
to: Global plant consolidations and
Acceleration in top line growth related tech transfers
Strong September sales
Zovirax stock out early in Q3
15
17. Acquisition, Integration, & Restructuring
Cash Costs
($ in millions)
Q3 12 Q2 12 Q1 12
Acquisition Related Restructuring/Integration $ 25.0 $ 36.6 $ 59.5
Biovail Merger Related Costs $ 25.9
Manufacturing Rationalization $ 2.3 $ 10.6 $ 1.9
IP Migration $ 5.4 $ 1.1
U.S. Commercial Restructuring $ 1.6
Total $ 34.2 $ 48.3 $ 87.3
16
18. Update on Recent Financings
Medicis Financing
7 year Term Loan B – to fund at close
$1.0 billion @ L+3.25 (1% LIBOR floor)
8 year High Yield Notes – closed into escrow
$1.75 billion @ 6 3/8%
Other Financings
8 year High Yield Notes - not tied to Medicis deal
$500 million @ 6 3/8%
Q4 2012 Impact
$35 million, or $0.12 Cash EPS, for Medicis related interest expense
$9 million, or $0.03 Cash EPS, for other financing
Pro forma for Medicis closing
Total debt = $10.9 billion
Leverage ratio = ~4.2X
17
19. Financial Guidance for 2012
Previous Guidance Current Guidance
Q4 2012 2012
Revenue $3.4 - $3.6 Revenue $900 M+ $3.4 - $3.6 B
billion
Cash EPS Excluding
Medicis Related $1.30 - $1.35 $4.60 - $4.65
$4.55 - $4.75 Cash
Financing
EPS
Cash EPS Including
$4.18 – $4.38
Medicis Related $1.18 - $1.23 $4.48 - $4.53
ex one-time Interest Expense
items
Cash EPS Excluding
Medicis Related $1.30 - $1.35 $4.23 - $4.28
> $1.4 billion in Interest Expense &
Adjusted Cash Flow One-time Items
from Operations Adjusted Cash Flow
from Operations $330 - $430 M $1.2 - 1.3 B
See Note 1 regarding guidance 18
